MedTrace Logo

GnRH-a and Pregnancy Rate in In Vitro Fertilization (IVF) Cycles.

NCT01269125 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2013-07-30

Study results available
· View outcomes & findings →

Summary

The investigators attempted to establish a rationale for the Gonadotropin Releasing Hormone-agonist (GnRH-a) administration, post-laparoscopically, in women with mild endometriosis (until stage II, according to AFS) who underwent IVF-ET procedure. Since GnRH-a reduces cytokine's concentration in serum (Iwabe et al., 1998; Iwabe et al., 2003) and peritoneal fluid of women with endometriosis (Taketani et al., 1992) the investigators hypothesized that GnRH-a can reduces also cytokine's concentration in the follicular fluid and this action may improve the oocyte quality and the fertility of these women.

Conditions

Interventions

DRUG

Leuprolide

single injection of 3.75 leuprolide every 28 days, 3 dosages

PROCEDURE

IVF

Assisted Reproduction Technique.

Sponsors & Collaborators

  • University of Patras

    collaborator OTHER

  • Tottori University Hospital

    collaborator OTHER

  • University of Ioannina

    lead OTHER

Principal Investigators

  • Apostolos Kaponis, MD · Ioannina University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
29 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2010-08-31
Completion
2010-09-30

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01269125 on ClinicalTrials.gov